41 related articles for article (PubMed ID: 32878814)
21. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T;
BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Ushijima K; Kamura T; Tamura K; Kuzuya K; Sugiyama T; Noda K; Ochiai K
Int J Clin Oncol; 2013 Feb; 18(1):126-31. PubMed ID: 22127346
[TBL] [Abstract][Full Text] [Related]
23. Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.
Machiels JP; Van Maanen A; Vandenbulcke JM; Filleul B; Seront E; Henry S; D'Hondt L; Lonchay C; Holbrechts S; Boegner P; Brohee D; Dequanter D; Louviaux I; Sautois B; Whenham N; Berchem G; Vanderschueren B; Fontaine C; Schmitz S; Gillain A; Schoonjans J; Rottey S
Oncologist; 2016 Dec; 21(12):1416-e17. PubMed ID: 27903924
[TBL] [Abstract][Full Text] [Related]
24. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
25. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
26. The clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review.
Wang X; Wang S; Yao S; Shi W; Ma K
J Ovarian Res; 2022 Sep; 15(1):104. PubMed ID: 36114551
[TBL] [Abstract][Full Text] [Related]
27. Statins as adjuvants in the treatment of ovarian cancer: Controversy and misunderstanding.
Manzano-León N; Garcia-Lopez P
Eur J Pharmacol; 2021 Apr; 896():173915. PubMed ID: 33513335
[TBL] [Abstract][Full Text] [Related]
28. Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?
Herzog TJ; Monk BJ
Gynecol Oncol Res Pract; 2017; 4():13. PubMed ID: 28904804
[TBL] [Abstract][Full Text] [Related]
29. New strategies in ovarian cancer treatment.
Lee JM; Minasian L; Kohn EC
Cancer; 2019 Dec; 125 Suppl 24(Suppl 24):4623-4629. PubMed ID: 31967682
[TBL] [Abstract][Full Text] [Related]
30. Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer.
Madsen CV; Adimi P; Jakobsen A; Steffensen KD
Anticancer Res; 2020 Sep; 40(9):5255-5261. PubMed ID: 32878814
[TBL] [Abstract][Full Text] [Related]
31. Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review.
Jin M; Cai J; Wang X; Zhang T; Zhao Y
Cancer Biol Ther; 2018; 19(12):1088-1092. PubMed ID: 30110192
[TBL] [Abstract][Full Text] [Related]
32. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies.
Vasey PA
Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S23-8. PubMed ID: 14661043
[TBL] [Abstract][Full Text] [Related]
33. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.
Wilson MK; Pujade-Lauraine E; Aoki D; Mirza MR; Lorusso D; Oza AM; du Bois A; Vergote I; Reuss A; Bacon M; Friedlander M; Gallardo-Rincon D; Joly F; Chang SJ; Ferrero AM; Edmondson RJ; Wimberger P; Maenpaa J; Gaffney D; Zang R; Okamoto A; Stuart G; Ochiai K;
Ann Oncol; 2017 Apr; 28(4):727-732. PubMed ID: 27993805
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
